solo per uso di ricerca

Ribavirin (ICN-1229) Antiviral chemical

N. Cat.: S2504

Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
Ribavirin (ICN-1229) Antiviral chemical Chemical Structure

Struttura chimica

Peso molecolare: 244.20864

Vai a

Controllo Qualità (Quality Control)

Lotto: Purezza: 99.97%
99.97

Coltura cellulare, trattamento e concentrazione di lavoro
(Cell Culture, Treatment & Working Concentration)

Linee cellulari Tipo di saggio Concentrazione Tempo di incubazione Formulazione Descrizione dell'attività PMID
E6SM cell lines Function assay Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines, EC50=0.005 μM
MDCK cells Function assay 3 days Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis, EC50=0.094 μM
mouse L1210 cells Function assay 20-60 mins Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins, IC50=1 μM
human CEM cells Function assay 20-60 mins Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins, IC50=1 μM
BHK21 cell line Function assay Inhibition of West Nile virus VLP replicon in BHK21 cell line, EC50=1.1 μM
HeLa cell Function assay Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines, EC50=1.5 μM
MDCK cells Function assay 36 h Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs, IC50=1.9 μM
MDBK cells Function assay 2 days Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR534 infected in MDBK cells assessed as reduction of viral cytopathic effect after 2 days bt MTS assay, EC50=4.6 μM
african green monkey Vero cells Function assay 5 days Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay, EC50=7 μM
HEL cells Function assay 2-3 days Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50=10 μM
HEK293 cells Function assay 24 h Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay, EC50=15 μM
human BE(2)-C cells Function assay 18-20 h Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as inhibition of viral RNA replication after 18 to 20 hrs by luciferase reporter gene assay, IC50=16 μM
human HuH7-J20 cells Function assay Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs, EC50=30.4 μM
human MT4 cells Cytotoxic assay 96 h Cytotoxicity against human MT4 cells after 96 hrs by MTT assay, CC50=31 μM
human HuH7 cells Cytotoxic assay 3 days Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay, CC50=32 μM
human KB cells Function assay 72 h Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control
human KB cells Function assay 1-1000 μg/ml 72 h Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs
Clicca per visualizzare più dati sperimentali sulle linee cellulari

Informazioni chimiche, conservazione e stabilità (Chemical Information, Storage & Stability)

Peso molecolare 244.20864 Formula

C8H12N4O5

Conservazione (Dalla data di ricezione)
N. CAS 36791-04-5 Scarica SDF Conservazione delle soluzioni stock

Sinonimi NSC-163039, RTCA, Tribavirin Smiles C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N

Solubilità (Solubility)

In vitro
Lotto:

DMSO : 49 mg/mL (200.64 mM)
(Il DMSO contaminato da umidità può ridurre la solubilità. Utilizzare DMSO fresco e anidro.)

Water : 49 mg/mL

Ethanol : Insoluble

Calcolatore di Molarità

Massa Concentrazione Volume Peso molecolare
Calcolatore di Diluizione Calcolatore del Peso Molecolare

In vivo
Lotto:

Calcolatore di formulazione in vivo (Soluzione chiara)

Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)

mg/kg g μL

Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Risultati del calcolo:

Concentrazione di lavoro: mg/ml;

Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )

Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.

Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.

Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.

Meccanismo d'azione (Mechanism of Action)

In vitro
Ribavirin (ICN-1229) significantly reduces the efficiency with which progeny subgenomic replicons transfect new cells in the replicon system, although it has little effect on levels of HCV replication. This compound increases the mutation frequency of HCV, with the highest rates of mutations being found in the NS5A-encoding region. It enhances TH1 while inhibiting T 2 cytokine production by stimulated T cells. Ribavirin shows antiviral activity against a variety of RNA viruses and is used in combination with interferon-alpha to treat hepatitis C virus infection. It reduces infectious poliovirus production to as little as 0. 00001% in cell culture. Its antiviral activity is exerted directly through lethal mutagenesis of the viral genetic material. This compound markedly reduces viral-induced parameters of macrophage activation at physiologic concentrations (up to 500 mg/mL). It inhibits the production of IL-4 by Th2 cells, whereas it does not diminish the production of IFN-gamma in Th1 cells. Ribavirin exhibits antiviral activity against a broad range of both DNA and RNA viruses in vitro. It is a cytostatic agent and causes a reduction in synthesis of DNA, RNA and proteins in exposed cells. It is thought to induce a switch in T-helper cell phenotype from type 2 to type 1.
Riferimenti
  • [4] https://pubmed.ncbi.nlm.nih.gov/9531310/
  • [5] https://pubmed.ncbi.nlm.nih.gov/16287208/

Applicazioni (Applications)

Metodi Biomarcatori Immagini PMID
Western blot p53 / p-p53 / p21 / Mdm2 EZH2 / p-ERK / ERK / p-eIF4E / eIF4E / p21 Cyclin D1 p-AKT / AKT / pBP1 / BP1
S2504-WB1
22962590
Growth inhibition assay Cell number
S2504-viability1
21415224

Informazioni sullo studio clinico (Clinical Trial Information)

(dati da https://clinicaltrials.gov, aggiornato il 2024-05-22)

Numero NCT Reclutamento Condizioni Sponsor/Collaboratori Data di inizio Fasi
NCT05940545 Recruiting
CCHF
Liverpool School of Tropical Medicine
July 12 2023 Phase 1|Phase 2
NCT04283513 Not yet recruiting
Hemorrhagic Fever
U.S. Army Medical Research and Development Command
October 31 2022 Phase 2
NCT04335123 Completed
COVID-19
University of Kansas Medical Center
April 4 2020 Phase 1
NCT04285034 Completed
Lassa Fever
University of Oxford
November 26 2019 --
NCT03889106 Terminated
Lassa Fever
University of Oxford|National Institute for Health Research United Kingdom|Kenema Government Hospital|London School of Hygiene and Tropical Medicine|Public Health England
March 1 2019 --
NCT03585725 Terminated
Follicular Lymphoma|Mantle Cell Lymphoma
Weill Medical College of Cornell University|Memorial Sloan Kettering Cancer Center
September 26 2018 Early Phase 1